IP Library Granted Patent US 9,782,368
Granted Patent B2
US 9,782,368 · App. 15/129,654 · Granted Oct 10, 2017

Use of N,N-bis-2-mercaptoethyl isophthalamide

Inventors: Boyd Eugene Haley (Nicholasville, KY); Ragnar Axel Theodor Klingberg (Stockholm, SE)
Assignee: Emeramed Limited
A61K31/166A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,368
App. No.
15/129,654
Granted
Oct 10, 2017
Kind
B2
Abstract

According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in regenerating ascorbate systemically and thus in the therapeutic treatment of chronic obstructive pulmonary disease.

Claims (11)

1. A method of treatment of chronic obstructive pulmonary disease, which method comprises the administration of N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.

2. A method as claimed in claim 1 , wherein the dose of N,N-bis-2-mercaptoethyl isophthalamide or salt thereof that is administered is capable of regenerating ascorbate systemically.

3. A method of reducing the risk of respiratory morbidity and/or mortality in a patient, which method comprises administering N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt thereof, to such a patient exhibiting symptoms of chronic obstructive pulmonary disease.

4. A method of relieving one or more symptom of chronic obstructive pulmonary disease in a patient suffering therefrom, which method comprise administering N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or thereof, to such a patient.

5. A method as claimed in claim 4 , wherein the symptom is skeletal muscle fatigue and/or cough/sputum production.

6. A method as claimed in claim 1 , wherein the patient is a smoker or an ex-smoker.

7. A method as claimed in claim 6 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from a bronchodilator, an anticholinergic drug, or a corticosteroid.

8. A method as claimed in claim 3 , wherein the patient is a smoker or an ex-smoker.

9. A method as claimed in claim 8 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from a bronchodilator, an anticholinergic drug, or a corticosteroid.

10. A method as claimed in claim 4 , wherein the patient is a smoker or an ex- smoker.

11. A method as claimed in claim 10 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from a bronchodilator, an anticholinergic drug, or a corticosteroid.

Assignments (2)
CHANGE OF ADDRESS Recorded Jul 18, 2017
From: EMERAMED LIMITED
To: EMERAMED LIMITED
Reel/Frame 043218/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2016
From: HALEY, BOYD EUGENE; KLINGBERG, RAGNAR AXEL THEODOR
To: EMERAMED LIMITED
Reel/Frame 039872/0323 →
Priority Claims (1)
GB 1406115.4 · Apr 4, 2014 · national
Continuity (1)
Related Publication 20170157072A1 · Jun 8, 2017